Tokai Pharmaceuticals (TKAI) Shares are Up 17.93%

Tokai Pharmaceuticals (TKAI) : Traders are bullish on Tokai Pharmaceuticals (TKAI) as it has outperformed the S&P 500 by a wide margin of 14.94% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 17.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.93% in the last 1 week, and is up 12.61% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 12.51% and the 50-Day Moving Average is 44.02%.The 200 Day SMA reached 78.28% Tokai Pharmaceuticals, Inc. has dropped 79.51% during the last 3-month period . Year-to-Date the stock performance stands at -85.67%.


Tokai Pharmaceuticals (TKAI) : Average target price received by Tokai Pharmaceuticals (TKAI) is $1.68 with an expected standard deviation of $0.47. The most aggressive target on the stock is $2, whereas the most downbeat target is $1. 4 financial analysts are currently covering the stock.

Company shares have received an average consensus rating of Hold for the current week Tokai Pharmaceuticals (NASDAQ:TKAI): stock was range-bound between the intraday low of $1.21 and the intraday high of $1.3 after having opened at $1.25 on Fridays session. The stock finally closed in the red at $1.25, a loss of -2.34%. The stock remained in the red for the whole trading day. The total traded volume was 1,464,664 shares. The stock failed to cross $1.3 in Fridays trading. The stocks closing price on Thursday was $1.25.

Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Companys lead drug candidate galeterone is a multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC), whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone, known as ARMOR2 trial, for the treatment of multiple CRPC populations.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.